KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Total Debt: 2010-2024

Historic Total Debt for Pacira BioSciences (PCRX) over the last 13 years, with Dec 2024 value amounting to $585.3 million.

  • Pacira BioSciences' Total Debt rose 22.12% to $376.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $376.7 million, marking a year-over-year increase of 22.12%. This contributed to the annual value of $585.3 million for FY2024, which is 372.63% up from last year.
  • According to the latest figures from FY2024, Pacira BioSciences' Total Debt is $585.3 million, which was up 372.63% from $123.8 million recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Total Debt registered a high of $685.7 million during FY2021, and its lowest value of $123.8 million during FY2023.
  • Its 3-year average for Total Debt is $331.3 million, with a median of $284.7 million in 2022.
  • Its Total Debt has fluctuated over the past 5 years, first tumbled by 58.48% in 2022, then soared by 372.63% in 2024.
  • Yearly analysis of 5 years shows Pacira BioSciences' Total Debt stood at $149.6 million in 2020, then surged by 358.23% to $685.7 million in 2021, then crashed by 58.48% to $284.7 million in 2022, then plummeted by 56.50% to $123.8 million in 2023, then soared by 372.63% to $585.3 million in 2024.